|
시장보고서
상품코드
2078022
항경련제 시장 : 약물 계열별, 투여 경로별, 적응증별, 유통 채널별, 지역별 규모, 점유율, 전망 및 기회 분석(2025-2032년)Anticonvulsant Drugs Market, by Drug Class, by Route of Administration, by Indication, by Distribution Channel, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
항경련제 시장은 2026년에 73억 8,700만 달러 규모가 될 것으로 추정되며, 2033년까지 87억 2,110만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 2.4%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 73억 8,700만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 2.40% | 2033년 시장 규모 예측: | 87억 2,110만 달러 |
항경련제는 간질 발작 치료에 사용되는 다양한 종류의 약물입니다. 많은 항경련제는 기분 안정제 역할도 하는 경향이 있기 때문에 신경성 통증, 양극성 장애, 경계성 인격 장애의 치료에도 더욱 빈번하게 사용되고 있습니다. 가바펜틴, 카르바마제핀, 발프로산 등의 항경련제는 신경세포 수준에서 나트륨 채널(발프로산 및 가바펜티노이드 계열 약물) 또는 칼슘 채널(카르바마제핀 및 옥스카르바제핀)을 억제함으로써 만성 통증을 완화하는 것으로 여겨집니다. 이로 인해 자발적인 전기적 활동이 억제되어, 정상적인 신경 전도에 영향을 미치지 않으면서 과민한 통각 수용 신경세포의 탈분극에 대한 정상적인 역치가 회복됩니다.
신경병성 통증이나 기분 장애가 있는 환자는 이러한 약물로 가장 큰 혜택을 받습니다. 항경련제는 1세대(기존형) 약물과 2세대 약물로 분류됩니다. 2세대 항경련제는 일반적으로 기존 항경련제보다 내약성이 우수하며, 치료 범위도 더 넓습니다. 약물 선택은 발작의 종류에 따라 이루어집니다. 부분 발작에 대한 1차 치료제로는 라모트리진이나 레베티라세탐이 있으며, 전신 발작에는 발프로산이 사용됩니다. 모든 항경련제에는 중추신경계에 미치는 용량 의존성 부작용(예 : 졸음, 메스꺼움)이 있지만, 일부 약제에는 그 밖의 부작용(예 : 페니토인으로 인한 치은 과형성)도 있습니다.
시장 역학
간질 유병률의 증가가 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 세계보건기구(WHO)에 따르면 2022년 2월 기준으로 간질은 전 세계적으로 가장 흔한 신경 질환 중 하나이며, 약 5,000만 명이 이 질환을 앓고 있습니다. 간질 환자의 80% 가까이가 저·중소득 국가에 거주하고 있습니다. 같은 소식통에 따르면, 간질을 앓고 있는 사람들의 최대 70%는 적절한 진단과 치료를 받으면 발작 없는 생활을 영위할 수 있을 것으로 추정됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 항목(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 시장 전략)을 바탕으로 전 세계 항경련제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 항경련제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 항경련제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 세계의 항경련제 시장 인사이트
제4장 세계의 항경련제 시장 : 약물 계열별, 2021-2033년
제5장 세계의 항경련제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 항경련제 시장 : 적응증별, 2021-2033년
제7장 세계의 항경련제 시장 : 유통 채널별, 2021-2033년
제8장 세계의 항경련제 시장 : 지역별, 2021-2033년
제9장 기업 개요
제10장 섹션
KSM 26.07.09Anticonvulsant Drugs Market is estimated to be valued at USD 7,387.0 Mn in 2026 and is expected to reach USD 8,721.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7,387.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 2.40% | 2033 Value Projection: | USD 8,721.1 Mn |
Anticonvulsants are a broad class of drugs used to treat epileptic seizures. Since many anticonvulsants tend to operate as mood stabilizers, they are also being used more frequently to treat neuropathic pain, bipolar disorder, and borderline personality disorder. Anticonvulsants, including gabapentin, carbamazepine, and valproic acid, are believed to alleviate chronic pain by obstructing sodium (valproate and the gabapentanoids) or calcium (carbamazepine and Oxcarbazepine) channels at the cellular neuronal level. This suppresses spontaneous electrical activity and restores the normal threshold to depolarization of hypersensitive nociceptive neurons without affecting normal nerve conduction.
Patients with neuropathic pain and mood disorders benefit most from these drugs. Anticonvulsant drugs are classified as either first-generation (classic) agents or second-generation agents. Second-generation anticonvulsants are usually better tolerated and have a broader therapeutic range than classic anticonvulsant drugs. The choice of drug is guided by the type of seizure. First-line treatment for focal seizures includes lamotrigine or levetiracetam, while valproate is used for generalized seizures. While all anticonvulsants have dose-dependent side effects on the central nervous system (e.g., somnolence, nausea), select agents also have other side effects (e.g., gingival hyperplasia caused by phenytoin).
Market Dynamics
Increasing prevalence of epilepsy is expected to propel the market growth over the forecast period. For instance, according to the World Health Organization, in February 2022, epilepsy is one of the most common neurological diseases globally, which affects around 50 million people. Nearly 80% of people with epilepsy live in low- and middle-income countries. According to the same source, it is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anticonvulsant drugs market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global anticonvulsant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticonvulsant drugs market
Detailed Segmentation:
- Global Anticonvulsant Drugs Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Barbiturates
- Benzodiazepines
- Aromatic allylic alcohols
- Carboxamides
- Triazine
- AMPA receptor antagonists
- Carbamate
- Hydantoin
- Fatty Acid Derivative
- GABA analogs
- Valproylamides
- Others (Propionates, Oxazolidinediones, etc.)
- Global Anticonvulsant Drugs Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Enteral
- Parenteral
- Global Anticonvulsant Drugs Market, By Indication (Revenue, USD Mn, 2021 - 2033)
- Epilepsy
- Neuropathic pain
- Anxiety
- Fibromyalgia
- Bipolar Disorder
- Others (Borderline personality disorder, etc.)
- Global Anticonvulsant Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anticonvulsant Drugs Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- Company Profiles
- Novartis AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Alkem Labs
- SK BIOPHARMACEUTICALS
- Eisai Co., Ltd
- Angelini S.p.a.
- Sun Pharmaceutical Industries Ltd.
- UCB S.A.
- Unichem Laboratories
- Jazz Pharmaceuticals, Inc.
- Neuropathix, Inc.
- Xenon Pharmaceuticals, Inc.
- SK Life Science, Inc.
- Sumitomo Pharma Co., Ltd
- Bausch Health Companies Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Market Opportunity Map
3. Global Anticonvulsant Drugs Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Key Developments
- Regulatory Scenario
- Merger & Acquisition Scenario
- Pricing Analysis
- Brand Mapping
4. Global Anticonvulsant Drugs Market, By Drug Class, 2021 - 2033 (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Barbiturates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Aromatic allylic alcohols
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Carboxamides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Triazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- AMPA receptor antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Carbamate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Hydantoin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Fatty Acid Derivative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- GABA analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Valproylamides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Others (Propionates, Oxazolidinediones, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
5. Global Anticonvulsant Drugs Market, By Route of Administration, 2021 - 2033 (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Enteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
6. Global Anticonvulsant Drugs Market, By Indication, 2021 - 2033 (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Neuropathic pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Anxiety
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Fibromyalgia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Others (Borderline personality disorder, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
7. Global Anticonvulsant Drugs Market, By Distribution Channel, 2021 - 2033 (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033 (US$ Million)
8. Global Anticonvulsant Drugs Market, By Region, 2021 - 2033 (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Region at Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Million)
- South Africa
- Central Africa
- North Africa
9. Company Profiles
- Novartis AG*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zogenix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- DR. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alkem Labs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SK BIOPHARMACEUTICALS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Angelini S.p.a.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Unichem Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jazz Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Neuropathix, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xenon Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SK Life Science, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sumitomo Pharma Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About us
